Bacterial Pneumonia Market to Grow with a CAGR of 7.18% through 2028
Rising precision
medicine, offering personalized treatment approaches are expected to drive the
Global Bacterial Pneumonia Market growth in the forecast period, 2024-2028.
According
to TechSci Research report, “Bacterial Pneumonia Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Bacterial Pneumonia Market stood at USD 2.52 billion in 2022 and is
anticipated to grow with a CAGR of 7.18% in the forecast period, 2024-2028. The
global bacterial pneumonia market is experiencing significant growth, driven by
various key market drivers that are shaping the landscape of this critical
healthcare sector. Bacterial pneumonia, a common and potentially
life-threatening respiratory infection caused by different bacterial pathogens,
poses a considerable health burden worldwide. One of the foremost drivers of
the global bacterial pneumonia market is the rising incidence of this
infectious disease. Bacterial pneumonia affects individuals across all age
groups, with a particular impact on vulnerable populations such as children,
the elderly, and individuals with weakened immune systems. Factors like smoking,
chronic respiratory conditions, and environmental pollutants contribute to the
prevalence of bacterial pneumonia. As the global population grows and ages, the
number of people at risk of contracting this respiratory infection is
increasing, driving the demand for prevention, diagnosis, and treatment
solutions.
Advancements in
medical research and technology have played a pivotal role in boosting the
bacterial pneumonia market. Researchers have made significant strides in
understanding the various bacterial pathogens responsible for pneumonia and
have developed more accurate diagnostic methods. Molecular testing, advanced
imaging techniques, and next-generation sequencing have improved the accuracy
and speed of pneumonia diagnosis, enabling healthcare providers to initiate
timely and targeted treatment strategies. These technological innovations have
enhanced patient outcomes and reduced the mortality associated with bacterial
pneumonia. The emergence of drug-resistant bacterial strains has created a pressing
need for novel therapeutic options, driving innovation within the bacterial
pneumonia market. Antibiotic resistance is a growing concern, making it
challenging to treat infections effectively. To address this, pharmaceutical
companies and research institutions are investing in the development of new
antibiotics, innovative treatment strategies, and combination therapies. These
efforts aim to combat drug-resistant bacteria and provide effective solutions
for bacterial pneumonia treatment, thereby driving market growth.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Bacterial Pneumonia Market”
Evolving
healthcare policies and vaccination programs are pivotal drivers in the fight
against bacterial pneumonia. Governments and healthcare organizations worldwide
are increasingly recognizing the economic and public health burden posed by
pneumonia. As a result, they are implementing policies to improve vaccination
coverage and enhance healthcare access. Vaccines have proven to be one of the
most effective means of preventing bacterial pneumonia, particularly in
children and the elderly. Increased vaccination efforts and awareness campaigns
are contributing to market growth by reducing the incidence of bacterial
pneumonia.
The Global
Bacterial Pneumonia Market is segmented into Type, Treatments, Route of
Administration, Distribution Channel, Regional Distribution, And Company.
Based on the
Route of Administration, the oral segment emerged as the dominant segment in
the global market for Global Bacterial Pneumonia Market in 2022. ral antibiotics are typically administered in
the form of pills, capsules, or liquids, making them easy for patients to
self-administer at home. This convenience is especially crucial for individuals
with mild to moderate cases of bacterial pneumonia who can continue their
treatment outside of a hospital setting. It allows for greater patient
compliance with prescribed treatment regimens. Many cases of bacterial
pneumonia, particularly Community-Acquired Pneumonia (CAP), can be managed on
an outpatient basis. Oral antibiotics facilitate outpatient treatment, reducing
the burden on healthcare facilities and resources. Patients with CAP can
receive oral antibiotic prescriptions from their healthcare providers and
complete their treatment at home, freeing up hospital beds for more severe
cases.
Based on the Treatment,
the Vaccines segment emerged as the dominant player in the global market for
Global Bacterial Pneumonia Market in 2022. Vaccines are primarily designed for
prevention, and they play a crucial role in reducing the incidence of bacterial
pneumonia. They stimulate the immune system to recognize and mount a defense
against specific bacterial pathogens, such as Streptococcus pneumoniae and
Haemophilus influenzae. By preventing infection in the first place, vaccines
significantly reduce the need for treatment, hospitalization, and associated
healthcare costs. Bacterial
pneumonia, especially Community-Acquired Pneumonia (CAP), affects a broad
demographic, including vulnerable populations like children and the elderly.
Vaccination campaigns targeting these high-risk groups have been successful in
reducing the burden of pneumonia-related hospitalizations and deaths. The
public health impact of vaccines is substantial, making them a priority in the
fight against bacterial pneumonia.
Based on the
Distribution Channel, the Retail Pharmacies segment emerged as the dominant
player in the global market for Global Bacterial Pneumonia Market in 2022 Retail pharmacies are easily accessible to the general
population. They are typically located in neighborhoods, towns, and cities,
making it convenient for individuals to obtain medications and products related
to bacterial pneumonia. Patients do not need to travel long distances or rely
solely on healthcare facilities, which may be more challenging to reach. Retail
pharmacies are staffed with trained pharmacists who can provide valuable
information and guidance to patients. Pharmacists can assist in medication
selection, dosing instructions, potential drug interactions, and side effects.
This expertise is especially important in the management of bacterial
pneumonia, where appropriate antibiotic use is crucial.
North America
Accounted for largest of the Market Share in Global Bacterial Pneumonia market.
in 2022, Owing to the strong healthcare infrastructure, high healthcare
expenditure, and a robust focus on research and development in the
pharmaceutical and healthcare sectors. The North American region, which
includes the United States and Canada, has historically been at the forefront
of medical innovation and has a well-established healthcare system that
contributes significantly to the dominance in the global bacterial pneumonia
market. The region is home to numerous
pharmaceutical companies and research institutions that are actively involved
in the development of antibiotics, vaccines, and treatment modalities for
bacterial pneumonia.
Major companies
operating in Global Bacterial Pneumonia Market are:
- Innoviva Inc
- Pfizer Inc.
- Merck & Co.,
Inc.
- Melinta Therapeutics
LLC
- Evopoint Biosciences
- Aridis
Pharmaceuticals Inc.
- Cumberland Pharmaceuticals
Inc.
- Eagle
Pharmaceuticals, Inc.
- Clarametyx
Biosciences
- Basilea
Pharmaceutica Ltd
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The
Global Bacterial Pneumonia market is poised for substantial growth in the
coming years, driven by several key factors. Firstly, the increasing incidence
of bacterial pneumonia, particularly among vulnerable populations like the
elderly and those with underlying health conditions, is expected to boost demand
for pneumonia-related healthcare services and products. Additionally,
advancements in medical research and technology are leading to the development
of innovative treatments, vaccines, and diagnostic tools, offering more
effective options for prevention and management. Furthermore, the rising
awareness about the importance of vaccination and early diagnosis, along with
government initiatives to combat antibiotic resistance, are likely to enhance
market growth.” said Mr. Karan Chechi, Research Director with TechSci Research,
a research-based management consulting firm.
“Bacterial
Pneumonia Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented By Type (Community-Acquired Pneumonia (CAP),
Hospital-Acquired Pneumonia (HAP)), By Treatments (Vaccines, Drugs), Route of
Administration (Oral, Subcutaneous, Other), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Competition”,
has evaluated the future growth potential of Global Bacterial Pneumonia Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Bacterial Pneumonia Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com